This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. I. Botez, MD; Pierre Mayer, MD; François Bellemare, PhD; Jacques Couture, MD

Arch Neurol. 1997;54(8):1030-1033.

Abstract
Background
Neurochemical disorders associated with spinocerebellar ataxias are multiple.

Objective
To use replacement and neuroprotective therapy in a case of severe respiratory failure in Friedreich ataxia.

Patient and Treatment
A 44-year-old man with severe Friedreich ataxia displayed arduous periodic breathing associated with minor desaturation as well as obstructive or mixed apneas associated with severe desaturation during the night. He was given oxitriptan (5-hydroxy-L-tryptophan) (1500 mg/d), thiamine hydrochloride (100 mg/d), and amantadine hydrochloride (100 mg/d). The first sleep study was conducted during the night before treatment, whereas the second was performed during the night after 9 months of treatment.

Results
After treatment, striking clinical improvement of spastic dysphonia was accompanied by significant diminution in the time spent in periodic breathing and in the number of obstructive and mixed apneas during the night. Controlled studies are needed.

Author Affiliations
From the Behavioral Neurology, Neurobiology, and Neuropsychology Unit (Dr Botez), the Sleep Research Laboratory of the Pneumology Service (Dr Mayer), and the Research Laboratory of the Department of Anesthesia (Drs Bellemare and Couture), Hôtel-Dieu Hospital, Montreal, Quebec.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?